TGF-β has been well accepted as an immunosuppressive cytokine in cancer progression, which can suppress the expression of chemokine receptor CXC motif 3 (CXCR3) in CD8 + T cells and thus limit the tumor trafficking (Gunderson et al., 2020). This evidence concerns the gene TGFB1 and neoplasm.